Pregnancy Clinical Trial
Official title:
Safety and Efficacy of Iodine Supplementation During Pregnancy With and Without Selenium Co-administration: Randomized Controlled Trial
In 1994, the WHO and UNICEF Joint Committee on Health Policy recommended Universal Salt
Iodization as a safe, cost-effective and sustainable strategy to ensure sufficient intake of
iodine by all individuals. However, it is still absent in Latvia.
A recent countrywide study in 2013 shows iodine deficiency among pregnant women in Latvia: 81
% of pregnant women had UIC levels below the WHO recommended range of 150-250 mcg/g Cr.
Because mild to moderate iodine deficiency during pregnancy can adversely affect fetal brain
development, WHO-UNICEF and ICCIDD advise an increase in the recommended daily dosage of
iodine to 250 mcg/day for pregnant women and breastfeeding women and 150 mcg/day for women in
the preconception period.
Data from a survey of the Latvian population indicate that approximately 100 mcg of iodine
per day is consumed through foods and iodized salt. To meet the increased iodine requirement
in pregnancy, pregnant women should take a supplement containing 150 mcg of iodine daily from
the earliest time possible.
A sudden increase in iodine intake in an iodine-deficient population may increase thyroid
autoimmunity. It is evident that thyroid disease has multiple adverse effects during
pregnancy and in the developing fetus especially in women with elevated serum anti-thyroid
antibody titers.
Studies have considered supplementing with selenium to reduce the risk of auto-immune
thyroiditis/post-partum autoimmune thyroid disease. Of the 11 trials of selenium
supplementation in patients with autoimmune thyroiditis, 7 have shown benefit with treatment
for 6 months or longer.
Aim of study is to approve that 150 mcg of iodine daily improves iodine status in pregnant
women and iodine 150 mcg in combination with selenium 100 mcg daily reduce risk of thyroid
autoimmunity.
Hypothesis of study is that 150 mcg iodine daily during pregnancy improves iodine status.
Iodine in combination with selenium is less associated with thyroid autoimmunity.
Study design: Pregnant women are randomized for either 150 mcg iodine intake daily or 150 mcg
iodine combined with 100 mcg selenium daily. Interventional group is compared with controls
without particular iodine supplementation.
Participants are asked to complete a questionnaire on dietary habits concerning iodine.
Thyroid function (thyroid-stimulating hormone, free thyroxine) and thyroperoxidase antibodies
(TPO-Ab) and urinary iodine are measured during first, second and third trimester of
pregnancy and week 8 after delivery in both, intervention and control group.
In 1994, the WHO and UNICEF Joint Committee on Health Policy recommended Universal Salt
Iodization as a safe, cost-effective and sustainable strategy to ensure sufficient intake of
iodine by all individuals. However, universal salt iodization is still absent in Latvia.
A recent countrywide study in 2013 shows iodine deficiency among pregnant women in Latvia.
The median Cr-standardized UIC was 80.8 (interquartile range (IQR) 46.1-130.6) mcg/g Cr or
69.4 (IQR 53.9-92.6) mcg/L during pregnancy, and 81 % of pregnant women had UIC levels below
the WHO recommended range of 150-250 mcg/g Cr.
Because mild to moderate iodine deficiency during pregnancy can adversely affect fetal brain
development, WHO-UNICEF and ICCIDD advise an increase in the recommended daily dosage of
iodine to 250 mcg/day for pregnant women and breastfeeding women and 150 mcg/day for women in
the preconception period.
Data from a survey of the Latvian population indicate that approximately 100 mcg of iodine
per day is consumed through foods and iodized salt. To meet the increased iodine requirement
in pregnancy, pregnant women should take a supplement containing 150 mcg of iodine daily from
the earliest time possible.
A sudden increase in iodine intake in an iodine-deficient population may increase thyroid
autoimmunity. Studies have connected induction of disease processes with thyroglobulin (Tg)
iodination, because hypo-iodinated Tg did not activate T cells; however, increasing the Tg
iodine content to even normal levels in vitro led to antigenicity of the molecule. It is
evident that thyroid disease has multiple adverse effects during pregnancy and the postpartum
period, and in the developing fetus especially in women with elevated serum anti-thyroid
antibody titers.
Previous studies have considered supplementing with selenium to reduce the risk of
auto-immune thyroiditis/post-partum autoimmune thyroid disease. Potential mechanisms may be
related to the selenoenzyme, GPx3, removing excess H2O2 produced in the thyrocyte for the
iodination of tyrosine to give thyroid hormones, thereby preventing thyrocyte damage.
Additionally, selenoprotein S (SEPS1) is involved in the control of the inflammatory response
in the endoplasmic reticulum. Of the 11 trials of selenium supplementation in patients with
autoimmune thyroiditis, 7 have shown benefit with treatment for 6 months or longer.
Aim of study is to approve that 150 mcg of iodine daily improves iodine status in pregnant
women and iodine 150 mcg in combination with selenium 100 mcg daily reduce risk of thyroid
autoimmunity.
Hypothesis of study is that 150 mcg iodine daily during pregnancy improves iodine status.
Iodine in combination with selenium is less associated with thyroid autoimmunity.
Study design: Pregnant women are randomized for either 150 mcg iodine intake daily or 150 mcg
iodine combined with 100 mcg selenium daily. Interventional group is compared with controls
without particular iodine supplementation.
Participants are asked to complete a questionnaire on dietary habits concerning iodine intake
at the moment they are recruited for study, at third trimester of pregnancy and week 8 after
delivery.
Thyroid function (thyroid-stimulating hormone (TSH), free thyroxine (fT4) and thyroperoxidase
antibodies (TPO-Ab) measures are assessed during first, second and third trimester of
pregnancy and week 8 after delivery in both, intervention and control group. Blood samples
are sent to the E. Gulbis Laboratory (Riga, Latvia), which operates according to EN ISO
15189:2008 standard. TSH, fT4 and TPO-Ab are measured by chemiluminescence immunoassay
(Siemens, Malvern, PA, USA).
Urinary iodine, using the ammonium persulfate method, is also measured in first, second,
third trimester of pregnancy and postpartum week 8 in intervention and control groups.
The urinary creatinine concentration is measured using the Jaffe method with the intention
that iodine concentration adjusted for creatinine concentration (iodine/Cr) could be
calculated. Creatinine standardized UIC is a more reliable method of iodine excretion than
random spot UIC measurement since there is a great day-to-day variability in water intake.
Statistical analysis includes pairwise comparison of 1) median (interquartile range) urinary
iodine concentration, median (IQR) or mean (SD) TSH, and median (IQR) or mean (SD) fT4; 2)
proportion (95%CI) of women with UIC below 150 mcg, TSH above trimester-specific norm, and
positive TPO antibodies among all three study groups at specific follow-up intervals.
Mann-Whitney U test or two-sided t-test is used for comparing continuous variables, whereas
chi2 test (or Fisher exact test) is used to compare proportions. If significant differences
observed at baseline, the change in those parameters from visit to visit is calculated and
compared. Logistic regression analysis is used to compare intervention groups with control
group in order to adjust for differences in baseline characteristics.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
| Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
| Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
| Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
| Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
| Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
| Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
| Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
| Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
| Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
| Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
| Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
| Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
| Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
| Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
| Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
| Terminated |
NCT02537145 -
PregnanT Moms Measure - Do-It-Yourself Health Monitoring and Simulation of Health in Pregnant Women
|